Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study

About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.

Our study aims to evaluate the complete resection rate at interval cytoreductive surgery for recurrent ovarian cancer patients, and to determine the safety and survival outcomes of this approach.

Inclusion Criteria:

• Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
• >= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
• Platinum-free interval should be >=6 months from the last dose of platinum-based chemotherapy
• Upfront SCR not feasible
• Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.
• Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.

Exclusion Criteria:

• Non-epithelial or borderline tumors are excluded
• Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.
• Patients using more than one line of chemotherapy are excluded.
• Patients who have platinum-resistant or refractory recurrence are excluded.
• Patients having second relapse or beyond are excluded.
• Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment